Status:
COMPLETED
A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.
Eligibility Criteria
Inclusion
- Adult patients 18 to 75 years of age with active RA
- Must have been taking MTX for at least 6 months
- No concurrent DMARD treatment (other than a stable dose of MTX)
Exclusion
- Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
- Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00395577
Start Date
November 1 2006
End Date
July 1 2007
Last Update
December 7 2007
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Call For Information
Dimitrovgrad, Bulgaria
2
Call For Information
Pleven, Bulgaria
3
Call For Information
Sofia, Bulgaria
4
Call For Information
Veliko Tarnovo, Bulgaria